Comparison of the Clinical Efficacy of Cefoperazone Sulbactam and Ceftazidime in the Treatment of Complicated Urinary Tract Infections  

作　　者：LUOHaiping 

机构地区：[1]LonghuiHospitalofTraditionalChineseMedicineofShaoyang,ShaoyangHu’nan422200,China

出　　处：《外文科技期刊数据库(文摘版)医药卫生》2022年第10期088-092,共5页

摘　　要：Objective: to compare and analyze the clinical efficacy of cefoperazone sulbactam and ceftazidime in the treatment of complicated urinary tract infections and to provide a theoretical basis for the clinical drug treatment of diseases. Methods: a retrospective study of 140 patients with complicated urinary tract infections admitted to the urology department of Hu’nan Provincial Peoples Hospital from January 2017 to December 2017: cefoperazone sulbactam group (71 patients, 1.0g / bid, 2 g/d) and (69 patients, 1.5g / bid, 3g / d), and PCT, CRP. Results: more cefoperazone subactam (70 / 71,94.29%) than ceftazidime (60 / 69,84.29%) were significant (P < 0.05). A total of 19 strains were detected in the cefoperazone and sulbactam group and 33 strains in the ceftazidime group, with a significant difference in the degree of bacterial clearance in the ceftazidim group (P < 0.05). Between groups, found that the bacterial clearance rate was higher in cefoperazone sulbactam group (84.21%) than in ceftazidime group (72.73%). Plasma PCT, CRP content were decreased compared to before treatment, and the difference between the groups was significant (P < 0.05). After treatment comparison, plasma PCT(0.21±0.15ng/m L) and CRP (0.68±5.24mg/L) content in cefoperazone sulbactam group were lower than those in ceftazidime group (0.87±0.32ng/m L), (20.49±6.81mg/L), and both differences were significant (P < 0.05). The cefoperazone sulbactam group (2.73 ± 0.95 days) and the treatment cost (1078.90 ± 375.44 yuan) were less than the ceftazidime group (6.97 ± 2.25 days) and (1141.69 ± 368.55 yuan), all statistically significant (P < 0.05). The incidence of adverse reactions between cefoperazone and sulbactam (1.40%) and ceftazidime (2.89%) was not significantly different (P > 0.05), and no serious adverse drug reactions occurred. Conclusion: cefoperazone subactam has better efficacy than ceftazidime for complicated urinary tract infections, mainly in bacterial clearance, course control and treatment cost. Patients with cefoperazone

关 键 词：cefoperazone sulbactam CEFTAZIDIME complicated urinary tract infection 

分 类 号：R969.4[医药卫生—药理学]